Nicholas J. Vogelzang, MD of Comprehensive Cancer Centers of Nevada discusses cost implications when abiraterone becomes standard care for prostate cancer treatment. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.
If abiraterone becomes the standard care will there be cost implications_
